<DOC>
	<DOC>NCT02511288</DOC>
	<brief_summary>The goal of this project is to create a biological collection of blood samples from patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) with clinical annotations.</brief_summary>
	<brief_title>LIquid BIopsies in Lung Cancer (LIBIL)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>COHORT 1 Patients with histologically confirmed advanced nonsmallcell lung carcinoma (stage IIIB/IV) regardless of the mutation status Inclusion at the time of diagnostic Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report Age ≥ 18 years Patients treated before their liquid biopsy COHORT 2 Inclusion criteria Patients with histologically confirmed advanced nonsmallcell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), BRaf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS portooncogene 1 (ROS1) translocation, Mesenchymalepithelial transition factor (MET) amplification, RET rearrangement. Inclusion at the time of diagnostic during followup or at relapse Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report Age ≥ 18 years Exclusion criteria Patients treated before their liquid biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematologic test</keyword>
</DOC>